Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia

Mokhtar, Sherif; Abdulrazzaq, Najiba; Chkhis, Ayman; aljasmi, alia

doi:10.5152/TurkThoracJ.2021.20255

Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia

Ayman CHKHİS, (Klinik Eczacılık Departmanı, Al Kuwait Hastanesi, Sağlık ve Önleme Bakanlığı, Dubai, Birleşik Arap Emirlikleri)

Najiba ABDULRAZZAQ, (Tıp Departmanı, Al Kuwait Hastanesi, Sağlık ve Önleme Bakanlığı, Dubai, Birleşik Arap Emirlikleri)

Sherif MOKHTAR, (Al Kuwait Hastanesi, Sağlık ve Önleme Bakanlığı, Dubai, Birleşik Arap Emirlikleri Radyoloji Departmanı)

Alia Al JASMİ (Klinik Eczacılık Departmanı, Al Kuwait Hastanesi, Sağlık ve Önleme Bakanlığı, Dubai, Birleşik Arap Emirlikleri)

Turkish Thoracic Journal

1 0

Yıl: 2021 Cilt: 22 Sayı: 3 Sayfa Aralığı: 199 - 204 Metin Dili: İngilizce DOI: 10.5152/TurkThoracJ.2021.20255 İndeks Tarihi: 01-10-2021

Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia

Öz:

The COVID-19 pandemic is progressing rapidly, sending the world into a great panic. Healthcare professionals haveresponded by embarking on a concerted search for therapies to cure and prevent COVID-19. Recently, interferon (IFN) has emerged as apotential therapy as it is associated with reducing lung inflammation and suppressing viral replication. This research paper assessed theefficacy of high-dose nebulized IFN α 2b in severe COVID-19 pneumonia.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Guo YR, Cao QD, Hong ZS et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7(1):11. [CrossRef]
2. Astuti I, Ysrafil. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr. 2020;14(4):407-412. [CrossRef]
3. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. [CrossRef]
4. Cascella M., Rajnik M, Cuomo A et al. Features, evaluation, and treatment of coronavirus. In: StatPearls. [Internet]. Treasure Island (FL): StatPearls Publishing; 2020
5. Arıkan H, Karadoğan D, Tokgöz Akyıl F et al. COVID-19 treatment at a glance. Turk Thorac J. 2020;21(6):438-445. [CrossRef]
6. Gao YM, Xu G, Wang B, Liu BC. Cytokine storm syndrome in coronavirus disease 2019: A narrative review [review]. J Intern Med. 2021;289(2):147-161. [CrossRef]
7. Nile SH., Nile A., Qiu J et al. COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66-70. [CrossRef]
8. Davidson S, Maini MK, Wack A, Maini.MK. Disease-promoting effects of Type I interferons in viral, bacterial, and coinfections. J Interferon Cytokine Res. 2015;35(4):252-264. [CrossRef]
9. Teijaro JR. Type I interferons in viral control and immune regulation. Curr Opin Virol. 2016;16:31-40. [CrossRef]
10. Essaidi-Laziosi M, Geiser J, Huang S et al. Interferon-dependent and respiratory virus-specific interference in dual infections of airway epithelia. Sci Rep. 2020;10(1):10246. [CrossRef]
11. Zhou Q, Chen V, Shannon CP et al. Interferon-α2b treatment for COVID-19. Front Immunol. 2020;11:1061. [CrossRef]
12. Hussain S, Xie YJ, Li D et al. Current strategies against COVID19. Chin Med. 2020;15:70. [CrossRef]
13. Charles PG, Wolfe R, Whitby M et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47(3):375-384. [CrossRef]
14. Sheshadri A, Shah DP, Godoy M et al. Progression of the Radiologic Severity Index predicts mortality in patients with parainfluenza virus-associated lower respiratory infections. PLOS ONE. 2018;13(5):e0197418. [CrossRef]
15. Geng Y, Wei Z, Qian H et al. Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019. Cardiovasc Pathol. 2020;47:107228. [CrossRef]
16. Dhochak N, Singhal T, Kabra SK, Lodha R. Pathophysiology of COVID-19: Why children fare better than adults? Indian J Pediatr. 2020;87(7):537-546. [CrossRef]
17. Rehman S, Majeed T, Ansari MA et al. Current scenario of COVID-19 in pediatric age group and physiology of immune and thymus response. Saudi J Biol Sci. 2020;27(10):2567-2573. [CrossRef]
18. Xu P, Huang J, Fan Z et al. Arbidol/IFN-α2b therapy for patients with coronavirus disease 2019: A retrospective multicenter cohort study. Microbes Infect. 2020;22(4-5):200-205. [CrossRef]
19. Matera MG, Rogliani P, Calzetta L., Cazzola M. Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. Respir Med. 2020;171:106114. [CrossRef]
20. Zimmermann P., Curtis N. Why is COVID-19 less severe in children ? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. 2020. [CrossRef]

APA	Chkhis A, Abdulrazzaq N, Mokhtar S, aljasmi a (2021). Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia. , 199 - 204. 10.5152/TurkThoracJ.2021.20255
Chicago	Chkhis Ayman,Abdulrazzaq Najiba,Mokhtar Sherif,aljasmi alia Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia. (2021): 199 - 204. 10.5152/TurkThoracJ.2021.20255
MLA	Chkhis Ayman,Abdulrazzaq Najiba,Mokhtar Sherif,aljasmi alia Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia. , 2021, ss.199 - 204. 10.5152/TurkThoracJ.2021.20255
AMA	Chkhis A,Abdulrazzaq N,Mokhtar S,aljasmi a Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia. . 2021; 199 - 204. 10.5152/TurkThoracJ.2021.20255
Vancouver	Chkhis A,Abdulrazzaq N,Mokhtar S,aljasmi a Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia. . 2021; 199 - 204. 10.5152/TurkThoracJ.2021.20255
IEEE	Chkhis A,Abdulrazzaq N,Mokhtar S,aljasmi a "Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia." , ss.199 - 204, 2021. 10.5152/TurkThoracJ.2021.20255
ISNAD	Chkhis, Ayman vd. "Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia". (2021), 199-204. https://doi.org/10.5152/TurkThoracJ.2021.20255

APA	Chkhis A, Abdulrazzaq N, Mokhtar S, aljasmi a (2021). Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia. Turkish Thoracic Journal, 22(3), 199 - 204. 10.5152/TurkThoracJ.2021.20255
Chicago	Chkhis Ayman,Abdulrazzaq Najiba,Mokhtar Sherif,aljasmi alia Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia. Turkish Thoracic Journal 22, no.3 (2021): 199 - 204. 10.5152/TurkThoracJ.2021.20255
MLA	Chkhis Ayman,Abdulrazzaq Najiba,Mokhtar Sherif,aljasmi alia Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia. Turkish Thoracic Journal, vol.22, no.3, 2021, ss.199 - 204. 10.5152/TurkThoracJ.2021.20255
AMA	Chkhis A,Abdulrazzaq N,Mokhtar S,aljasmi a Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia. Turkish Thoracic Journal. 2021; 22(3): 199 - 204. 10.5152/TurkThoracJ.2021.20255
Vancouver	Chkhis A,Abdulrazzaq N,Mokhtar S,aljasmi a Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia. Turkish Thoracic Journal. 2021; 22(3): 199 - 204. 10.5152/TurkThoracJ.2021.20255
IEEE	Chkhis A,Abdulrazzaq N,Mokhtar S,aljasmi a "Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia." Turkish Thoracic Journal, 22, ss.199 - 204, 2021. 10.5152/TurkThoracJ.2021.20255
ISNAD	Chkhis, Ayman vd. "Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia". Turkish Thoracic Journal 22/3 (2021), 199-204. https://doi.org/10.5152/TurkThoracJ.2021.20255